Member Info for Mancunian77

Bladerunneruk, with respect — the drop here has nothing to do with “poor online reviews.”

The whole value-retail and cosmetics sector has sold off on weak UK retail data and pre-Budget macro pressure.

Warpaint’s actual numbers (margins, cash, dividend, retail expansion) remain strong — that’s what institutions care about, not a handful of selective reviews.

Share price ≠ product quality.

Hard to see why anyone would be selling around 220p when W7L offers the potential to more than double over the next 6–9 months and pays a very healthy dividend in the meantime.

As others have noted — debt-free, cash-rich, ex-div next week (with payment also in November), and with macro tailwinds only getting stronger — patience here could be very well rewarded.

Https://www.theguardian.com/uk-news/2025/oct/22/rachel-reeves-budget-low-value-imports-tax-loophole-shein-temu?utm_source=chatgpt.com

Again, always worth remembering this isn’t “just another rollout” for W7L. It’s the first time the company has executed a coordinated, multi-retailer, multi-market expansion backed by stronger sell-through data, deeper retailer confidence, and a rock-solid balance sheet. That’s why the CEO called H2 “transformational” rather than “incremental.”

We’ll see the first wave of that impact in the upcoming H2 results.

If even 60–70% of these new doors deliver in line with historical averages, that alone could add several million pounds in revenue this half and meaningfully shift market sentiment.

The full-year contribution then rolls into FY26, setting the stage for potential earnings upgrades and a valuation re-rating as the story unfolds.

Excellent RNS this morning — Warpaint has appointed Berenberg as joint corporate broker alongside Shore Capital. That’s a clear vote of confidence in both the outlook and management’s ambition.

Companies don’t bring on a new broker unless they’re confident in their direction and looking to expand institutional engagement. Berenberg are one of Europe’s top-tier small & mid-cap brokers, highly selective about who they work with — so this speaks volumes.

The move should strengthen Warpaint’s market visibility, improve liquidity, and broaden fund access just as the major H2 rollouts are ramping up. Exactly the kind of proactive step you’d expect from a confident, growing business — not one on the back foot.

Confidence, not caution.

Always worth noting that Warpaint is starting to get more mainstream coverage again — even in broader market round-ups like this one from Kalkine Media. They highlight W7L alongside other listed names as a fast-growing cosmetics company with branded and private-label products, multi-channel distribution (wholesale, retail, international), and a clear position in the UK small-cap landscape.

👉 https://kalkinemedia.com/uk/news/market-updates/helios-underwriting-foresight-group-and-warpaint-london-across-ftse-100

Visibility like this matters — especially when the valuation is so depressed. Media and market commentators are increasingly framing W7L as a growth-oriented AIM success story rather than a company in trouble. That shift in narrative often happens before the wider market wakes up to the value story.

With a debt-free balance sheet, ~40% insider ownership, and major H2 retail rollouts now underway, that change in sentiment could act as a powerful catalyst once fundamentals and momentum start aligning.

Always worth remembering this isn’t “just another rollout” for W7L. It’s the first time the company has executed a coordinated, multi-retailer, multi-market expansion — backed by stronger sell-through data, deeper retailer confidence, and a rock-solid balance sheet. That’s why the CEO called H2 “transformational” rather than “incremental.”

We’ll see the first wave of impact in the H2 results — and if even 60–70% of these new doors perform in line with historical averages, that alone could add several million in revenue this half and materially improve sentiment. The full-year effect will then feed into FY26, setting up potential upgrades and a re-rating as the story unfolds.

“Turnover is vanity, profitability is sanity” — agreed. But W7L isn’t a story of chasing sales at any cost. It’s already profitable, debt-free, cash-rich and paying dividends, which is rare on AIM.

Roll-outs do come with upfront costs, but W7 has a track record of scaling in value channels like B&M and Home Bargains while maintaining c.40% gross margins. The same playbook is now being extended into Tesco, Boots, Superdrug, CVS etc.

Yes, retailers are ruthless on shelf space — but Schroders nudging their stake to 11.1% shows institutions believe the traction is there. They wouldn’t be quietly adding otherwise.

And it’s not just institutions — analysts are aligned too. Berenberg have a 510p price target and Shore Capital have it rated as a “House Stock”, reflecting confidence in execution and valuation upside.

As for online — W7 has never been a DTC-first brand. Its strength is impulse beauty at value price points in high-traffic bricks retail. That’s exactly where they’re now expanding.

Lots still to prove, sure. But they’re proving it step by step — and unlike many AIM names, they’re doing it from a position of financial strength.

Spot on 👌 — I’ve seen the same in Tesco, and placement by self-checkouts is gold dust for cheap, impulse cosmetics. That’s exactly where W7 belongs.

Also worth noting: Schroders just nudged their stake up past 11.1% as per today’s RNS. They were buying into the recent dip, not selling down. Institutions don’t chase size all at once — they build gradually.

Between visible rollouts in UK retail and smart money quietly accumulating, 215p looks like a proper floor. Once the overhang clears, this has Major upside. 🚀

Another positive – stronger £ = good for W7L. Most sourcing is USD-denominated, so a firmer pound cuts costs and lifts margins. With only ~5% sales in USD, the real swing is cheaper input costs → FX tailwind.

Good spot Stargate 👌 – the chart read ties in with the fundamentals too. Bands are widening after that tight consolidation and volumes suggest supply is being absorbed. If the squeeze resolves higher, 275–285p makes sense as the next resistance zone. With H2 rollouts (Tesco, Superdrug, Boots Xmas, CVS, Etos/Tigotà) only just starting to land, the technicals lining up with the fundamentals could set up a decent recovery leg from here.

Insiders are massively aligned here — founders Bazini & Macleod still own ~40% between them, and a NED bought stock this year. That’s real skin in the game alongside shareholders.

IC’s latest stance is still Buy. At 223p you’re paying

IC’s latest stance is still Buy. At 223p you’re paying

Berenberg on W7L: Buy, 510p target = 120%+ upside from here.

• H1 EPS 8.5p → full year looks like 18–20p EPS.

• On a sector-normal 25× P/E, that equates to 475–520p fair value.

• EBITDA view: guidance £23.5m–25.5m, current EV/EBITDA only ~7.5× vs peers on 12–14×. Even on 12× you’re at 365p, on 14× it’s 425p+, before factoring brand expansion.

• Plus: record 45% margins, £17m cash, zero debt, dividend hiked 14%, and locked-in H2 rollouts with Superdrug, Tesco, Boots, CVS, Etos and Tigotà.

👉 That’s why brokers see massive upside from ~230p today — fundamentals and growth drivers are intact.

Totally agree – H2 is where the real kicker comes. Rollouts already locked in: Superdrug +140, Tesco +150 impulse, Boots gifting in 350 stores for Xmas, plus CVS +399 stores in the US. Add in Etos Netherlands + Tigotà Italy expansions and you’ve got serious shelf space growth.

On top of that, price rises from H1 bite harder in H2, Europe orders are normalising, and Xmas gifting is always a big swing factor. With margins at 45% and £17m cash, they’re in great shape to deliver.

Yes, revenue came in just shy of guidance (£49.3m vs £50–52m), and FY forecasts were trimmed. But look at the underlying story:

• Gross margin hit 45% (45.5% ex-BA) – record level, proving pricing power & brand strength.

• Cash £17m, debt free – balance sheet is rock solid, stronger than ever.

• Dividend raised 14% – board clearly confident.

• Rest of World sales +144%, especially Australia, showing strong international traction.

• Direct online +48% – now nearly 7% of sales, with higher-margin potential.

• Brand Architekts contributing 12% of group sales already, acquired on bargain terms.

• H2 rollouts locked in: Superdrug +140, Tesco +150, Boots Xmas gifting (350 stores), CVS US +399 stores, plus Tigotà/Etos expansions in Europe.

FX losses and a one-off customer admin (Bodycare) hurt H1 PBT, but these are largely non-cash or exceptional. The engine is healthy, margins are climbing, and the pipeline for H2 is huge.

The market will react at as it sees fit, but fundamentally the medium-term story (UK, Europe, online, BA integration) is intact. Any weakness today will be an opportunity.

Relegation talk is just noise. Cut-off levels shift each quarter, plenty of names bounce in/out. Doesn’t change TW.’s fundamentals: £2.2bn order book, 9% yield, healthy cash, H2 margins improving. Even if it slipped out, history shows FTSE exits often rebound once passive selling clears. At ~0.85x book, TW. is a bargain — not a casualty.

Bit too negative IMO. Yes, H1 was soft, but TW. is still profitable at the trough, sitting on £327m net cash (guiding higher by year-end) and with a £2.2bn order book for 10k+ completions. Dividend isn’t just earnings-based but set at 7.5% of BV, which secures that sector-leading ~9% yield. Land creditors are standard across builders, and TW. has one of the strongest balance sheets in the sector. At ~100p (≈0.85x book), the very worst is already priced in — you’re effectively buying into the next cycle at fire-sale levels. October CMD could easily reset sentiment.

Old thinking there mate. TW. doesn’t run a fixed payout off earnings anymore – the dividend is now 7.5% of book value, not EPS. That’s why the ~9% yield is fully covered even in a soft year. Net cash still £327m at H1 after divs and cladding costs, completions + order book intact, and margins guided to improve in H2. Dividends aren’t uncovered – they’re structurally secured off a rock-solid balance sheet. At ~0.85× book, this is being priced like rates are 10%+, when they’re only ~4%. Huge upside once sentiment turns.